| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2025 |
| Sales | 447,390 | 433,710 | 424,500 | 327,810 | 0 |
| Sales Growth | +3.15% | +2.17% | +29.50% | unch | unch |
| Net Income | -10,510 | 6,050 | 5,920 | 15,760 | 0 |
| Net Income Growth | -273.72% | +2.20% | -62.44% | unch | unch |
Abcam Plc ADR (ABCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Abcam plc is a life sciences company. It researches, develops, and distributes biological reagents and tools for research, drug discovery and diagnostics. The company operates principally in in the United States, China, Japan, Germany, the United Kingdom and internationally. Abcam plc is based in Cambridge, the United Kingdom.
Fiscal Year End Date: 12/31